Lewes, DE -- (SBWire) -- 01/29/2018 --Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends
It is estimated that there are 3-4 times more intracellular targets than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody (mAb) therapies. Since many of these targets are not enzymes or surface receptoers with readily druggable pockets, these important oncogenic proteins cannot be easily inhibited with small molecules. Thus, intracellular cancer-specific proteins, such as mutated oncogene products, transcription factors, protein adapters, and other nontraditional targets, remain inaccessible to current technologies used for FDA-approved drugs.
Therefore, novel technologies are needed to address historically undruggable targets and complex mechanisms, such as intracellular protein-protein interactions like p53 or Ras, ?-catenin and Myc.
This report "Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends" brings you up-to-date regarding key technologies
- for identification and validation of intracellular targets,
- for generation of T-cell receptors (TCR) and TCR fusion proteins,
- for discovery of TCR-like antibodies, and
- for construction of cell-penetrating peptides, proteins and antibodies.
The report furthermore describes the profiles of leading product candidates created by these technologies. The technology companies are presented and analyzed. Deals between Big Pharma and technology companies as well as collaboration and licensing deals between technology companies are highlighted. The value of technologies and product candidates are discussed regarding company acquisition prices, economic deal terms and financing rounds.
What will you find in the report?
Description and comparison of technologies for
- Discovery and validation of intracellular targets;
- Discovery and optimization of T-Cell Receptors (TCRs);
- Generation of TCR-like or TCR-mimic antibodies;
- Generation of TCR fusion proteins
- Generation of cell-penetrating peptides, proteins and antibodies.
Presentation and discussion of profiles of selected product candidates:
- TCRL antibodies and TCR fusion proteins; and
- Cell-penetrating peptides, miniproteins and single domain and Ig antibodies
Spanning over 252 pages "Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends" report covers Executive Summary, Introduction & Overview, Background, Technology Profiles, Overview & Discussion, Technologies for Discovery of Intracellular Targets, Pipeline Analysis and Product Profiles, Stakeholder Analysis & Company Profiles, Deals & Financing, Trends & Outlook, References. This report Covered Companies few are - AstraZeneca, Atreca, BioNTech, Boehringer Ingelheim, Complix, Elasmogen, Eli Lilly, Eureka Therapeutics, Feldan Therapeutics, Fog Pharmaceuticals, Gadeta, Gilead Sciences (Kite Pharma), GlaxoSmith-Kline, Immatics Biotechnologies.
Please visit this link for more details: https://www.marketresearchreports.com/la-merie-publishing/intracellular-targets-made-druggable-tcr-antibodies-tcr-fusion-proteins-cell
Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare
About Market Research Reports, Inc.
Market Research Reports® Inc. is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.
Contact us for your market research requirements: http://www.marketresearchreports.com/contact
